# LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

> **NCT04216121** · — · RECRUITING · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 39 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

## Interventions

- **RADIATION:** Local ablative therapy
- **PROCEDURE:** Local ablative therapy

## Key facts

- **NCT ID:** NCT04216121
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-10
- **Primary completion:** 2025-10
- **Final completion:** 2025-10
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04216121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04216121, "LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04216121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*